ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO309

Urine Hydroxyproline as a Marker of Renal Dysfunction in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Son, Jongho, The Catholic University of Korea College of Medicine, Seoul, Korea (the Republic of)
  • Koh, Eun Sil, The Catholic University of Korea College of Medicine, Seoul, Korea (the Republic of)
  • Park, Cheol Whee, The Catholic University of Korea College of Medicine, Seoul, Korea (the Republic of)
  • Chung, Sungjin, The Catholic University of Korea College of Medicine, Seoul, Korea (the Republic of)
Background

Hydroxyproline (Hyp) is major component of the protein collagen in the tissues. Most of the Hyp released by the breakdown of collagen is degraded to free amino acid that circulates in plasma, is filtered, and is almost entirely reabsorbed by the kidney while some of the Hyp circulates in the peptide-bound form and are excreted in urine without further metabolism.
This study was designed to examine whether the measurement of urinary Hyp could be useful for assessing renal function in the patients with chronic kidney disease (CKD).

Methods

A total of 298 patients with various stages of non-dialytic CKD were included in this study. Values of total and free Hyp were measured from 24 hours urine and urininary free-to-total Hyp ratio was calculated to compare with known renal functional parameters (from January 5th, 2016 to May 7th, 2018)

Results

Median levels of urinary free Hyp and total Hyp are 0.70 mg/day (IQR 0.30-2.10 mg/day) and 125.00 μmol/day (IQR 80.00-196.00 μmol/day), respectively. Univariate linear regression analysis showed that urinary free-to-total Hyp ratio was correlated with creatinine (β=0.399, P<0.001), estimated glomerular filtration rate (eGFR; β=-0.213, P=0.001), cystatin C (β=0.338, P<0.001), proteinuria (β=0.181, P=0.004) and fractional excretion of sodium (β=0.141, P=0.023).
Results of multiple linear regression analysis showed that beta-coefficient of eGFR was –0.155 (P=0.084) for urinary free Hyp, 0.134 (P=0.091) for urinary total Hyp and –0.172 (P=0.042) for urinary free-to-total Hyp ratio, even after controlling for covariates, including age, gender and proteinuria.

Conclusion

Our results suggest that urinary free-to-total Hyp ratio would be used as a novel endogenous marker of renal dysfunction.